Here are five things to know:
1. Mr. McCarthy decided not to stand for re-election on the board to devote more time to his role as CEO and director of Z Genetics. He is also involved in other business ventures.
2. Mr. McCarthy will continue to serve out his term until the conclusion of InVivo’s 2016 Annual Meeting of Stockholders.
3. Since April 2013, Mr. McCarthy has been on the board of directors and served as chairman of the audit committee. He has also been the non-executive chairman of the board.
4. InVivo focuses on the Neuro-Spinal Scaffold solution for patients with spinal cord injury. The device is placed in the decompressed and debrided injury epicenter to support appositional healing.
5. The company is currently conducting clinical trials for the FDA and received the Humanitarian Use Device designation.
More articles on spine devices:
Stryker Spine acquires SafeWire, builds on MIS presence—5 things to know
K2M gaining foothold on complex spinal deformity market: 4 insights
DJO CFO, executive VP Susan Crawford to retire
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
